Wealthfront Advisers LLC Grows Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

Wealthfront Advisers LLC boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 37.1% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 8,142 shares of the biopharmaceutical company’s stock after buying an additional 2,202 shares during the quarter. Wealthfront Advisers LLC’s holdings in Regeneron Pharmaceuticals were worth $6,285,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also bought and sold shares of the company. Vanguard Group Inc. increased its position in Regeneron Pharmaceuticals by 0.3% in the fourth quarter. Vanguard Group Inc. now owns 9,075,153 shares of the biopharmaceutical company’s stock worth $7,004,838,000 after buying an additional 26,884 shares during the last quarter. Dodge & Cox increased its position in Regeneron Pharmaceuticals by 18.9% in the third quarter. Dodge & Cox now owns 4,550,845 shares of the biopharmaceutical company’s stock worth $2,558,804,000 after buying an additional 724,562 shares during the last quarter. Franklin Resources Inc. increased its position in Regeneron Pharmaceuticals by 6.0% in the third quarter. Franklin Resources Inc. now owns 2,453,143 shares of the biopharmaceutical company’s stock worth $1,379,329,000 after buying an additional 139,647 shares during the last quarter. Capital World Investors increased its position in Regeneron Pharmaceuticals by 1.6% in the third quarter. Capital World Investors now owns 1,998,366 shares of the biopharmaceutical company’s stock worth $1,123,609,000 after buying an additional 32,348 shares during the last quarter. Finally, Invesco Ltd. increased its position in Regeneron Pharmaceuticals by 38.0% in the third quarter. Invesco Ltd. now owns 1,484,473 shares of the biopharmaceutical company’s stock worth $834,675,000 after buying an additional 408,649 shares during the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN opened at $707.06 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.15 and a quick ratio of 3.39. The stock has a market capitalization of $74.75 billion, a price-to-earnings ratio of 17.23, a PEG ratio of 1.58 and a beta of 0.40. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $821.11. The business’s fifty day moving average price is $756.81 and its 200-day moving average price is $735.17.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, topping the consensus estimate of $8.91 by $0.56. The firm had revenue of $3.61 billion during the quarter, compared to analyst estimates of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.Regeneron Pharmaceuticals’s revenue was up 19.0% on a year-over-year basis. During the same period in the prior year, the business posted $8.22 EPS. On average, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.98 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th will be paid a $0.94 dividend. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. The ex-dividend date is Wednesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio is 9.16%.

Analyst Ratings Changes

REGN has been the subject of several recent research reports. TD Cowen lifted their price target on Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the company a “buy” rating in a research report on Thursday, April 23rd. Zacks Research downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 6th. Bank of America upgraded Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and upped their price target for the stock from $627.00 to $860.00 in a research note on Wednesday, January 7th. Wells Fargo & Company cut their price target on Regeneron Pharmaceuticals from $825.00 to $800.00 and set an “equal weight” rating on the stock in a research note on Thursday. Finally, Oppenheimer restated an “outperform” rating and issued a $865.00 price target (up from $750.00) on shares of Regeneron Pharmaceuticals in a research note on Monday, February 2nd. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $825.68.

Insider Transactions at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $778.53, for a total value of $77,853.00. Following the completion of the sale, the director directly owned 17,803 shares in the company, valued at $13,860,169.59. This represents a 0.56% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Huda Y. Zoghbi sold 1,638 shares of the company’s stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $781.33, for a total value of $1,279,818.54. Following the completion of the sale, the director owned 1,703 shares of the company’s stock, valued at $1,330,604.99. This trade represents a 49.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 3,774 shares of company stock worth $2,942,738 in the last three months. Corporate insiders own 7.02% of the company’s stock.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Q1 results beat expectations: Regeneron reported Q1 revenue up 19% to ~$3.6B and non‑GAAP EPS of $9.47, beating estimates, driven by strong Dupixent demand and Libtayo. This underpins near‑term top‑line momentum. Reuters: Regeneron beats quarterly results
• Positive Sentiment: $3 billion buyback announced and dividend declared: Management authorized up to $3B in share repurchases and declared a $0.94 quarterly dividend, both shareholder-friendly actions that support EPS and investor returns. Seeking Alpha: buyback mention
• Positive Sentiment: Pipeline progress could drive medium‑term upside: Management reported C5 program milestones (pivotal PNH enrollment complete, positive Phase III for cemdisiran in gMG) and potential multi‑indication launches as soon as late‑2026 — important optionality beyond core franchises. Yahoo: C5 milestones & pipeline
• Neutral Sentiment: Analyst target adjustments but mixed ratings: Several shops trimmed price targets (RBC to $762, Wells Fargo to $800, Truist to $796, Barclays to $917) while many retained buy/overweight stances — suggests analysts are tuning models post‑earnings but still see upside. TickerReport/Benzinga: price target moves
• Neutral Sentiment: Analysts trimmed near‑term forecasts: Firms modestly cut forecasts after Q1, reflecting product mix and competitive assumptions; important to watch updated guidance and modeling revisions. Benzinga: analysts cut forecasts
• Negative Sentiment: Market punished stock on Eylea weakness and competitive risk: U.S. high‑dose Eylea sales underperformed expectations and competition in the retina market is intensifying — this drove the immediate post‑earnings weakness despite the beat. Yahoo: Eylea sales miss
• Negative Sentiment: Q1 net income decline: GAAP net income fell ~10% to $727M year‑over‑year, reflecting some one‑time items and mix; investors sensitive to margin and profitability trends may see this as a near‑term headwind. Pharma‑Technology: net income falls

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.